Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641 is registered in ClinicalTrials.gov with Mohammed M Milhem as lead sponsor.

NCT NCT01876641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01876641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Lead sponsor
Mohammed M Milhem
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2013
Completion date
September 30, 2018
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf-mutated metastatic melanoma, melanoma, metastatic melanoma, v600ebraf-mutated metastatic melanoma